Sign in
4

Changes in Ownership

MoonLake Immunotherapeutics Filed Acc 0001213900-26-071075

Chief Financial Officer sold 39,120 shares at $22.04 ($862,205)

  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
Bodenstedt Matthias Chief Financial Officer 2026-06-22 Sale 10b5-1 −39,120 $22.04 $862,205 1,115,435 D: show line 1 in the form
Open-market sales · 39,120 sh · avg $22.04 · $862,205
Loading xslF345X06/ownership.xml…